Background-High-density lipoproteins have antidiabetic properties in vitro. Furthermore, elevated high-density lipoprotein levels accompanying a genetic deficiency of cholesteryl ester transfer protein are associated with decreased levels of plasma glucose. We now investigate effects on glucose homeostasis of inhibiting cholesteryl ester transfer protein with torcetrapib. Methods and Results-A post hoc analysis of the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial was conducted to investigate effects of the cholesteryl ester transfer protein inhibitor torcetrapib on glycemic control in the 6661 diabetic patients in the trial. At baseline, there were no differences between the 2 treatment arms with respect to plasma glucose, insulin, hemoglobin A 1c , or the homeostasis model assessment of insulin resistance. After 3 months, the diabetic subjects taking the combination of torcetrapib plus atorvastatin had plasma glucose levels 0.34 mmol/L lower (PϽ0.0001) and insulin levels 11.7 U/mL lower (PϽ0.0001) than in those receiving atorvastatin alone. Homeostasis model assessment of insulin resistance values decreased from 49.1 to 47.3 (PϽ0.0001) in the torcetrapib/atorvastatin arm compared with an increase in homeostasis model assessment of insulin resistance in the atorvastatin arm. At the 6-month time point, the mean hemoglobin A 1c level in the atorvastatin arm was 7.29% compared with 7.06% in the torcetrapib/atorvastatin arm (PϽ0.0001). These effects of torcetrapib remained apparent for up to 12 months. Torcetrapib also lowered both glucose and insulin levels in the participants without diabetes mellitus, although the effects were not as great as in those with diabetes mellitus. Conclusions-Treatment with torcetrapib improves glycemic control in atorvastatin-treated patients with type 2 diabetes mellitus. It remains to be determined whether this effect is the consequence of raising high-density lipoprotein.at Clinical Trial Registration-http:www.clinicaltrials.gov. Unique identifier: NCT00134264. (Circulation. 2011;124:555-562.)
T ype 2 diabetes mellitus, a condition approaching epidemic proportions worldwide, is a major risk factor for the development of atherosclerotic cardiovascular disease. One factor that contributes to this risk is a dyslipidemia characterized by hypertriglyceridemia and a low level of high-density lipoprotein (HDL) cholesterol. 1 HDLs have a number of well-documented properties with the potential to inhibit the development of atherosclerosis. 2 HDLs also have potential antidiabetic properties, 3 with evidence in vitro that they enhance the uptake of glucose by skeletal muscle 4 and stimulate the synthesis and secretion of insulin from pancreatic ␤-cells. 5 Furthermore, the elevation of HDL cholesterol accompanying genetic cholesteryl ester transfer protein (CETP) deficiency is associated with decreased levels of plasma glucose. 6 This article addresses the possibility that an intervention that inhibits activity of CETP will improve glycemic control in patients with diabetes mellitus. To this end, we have conducted a post hoc analysis of the diabetic subgroup in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
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The ILLUMINATE study was a large-scale, clinical outcome trial designed to investigate the HDL-raising effects of the CETP inhibitor torcetrapib on cardiovascular events in high-risk patients. 7 The early termination of the trial because of a significant excess of deaths and cardiovascular events in the torcetrapib-treated arm initially cast doubt on the utility of CETP inhibition (or even HDL raising) as an atheroprotective strategy. However, post hoc analyses of the ILLUMINATE study, in combination with additional basic studies, suggest that the adverse outcome in people treated with torcetrapib may have been the consequence of off-target effects of the drug unrelated to CETP inhibition. 8 -11 This has provided the basis for conducting new trials designed to test the atheroprotective properties of other CETP inhibitors, such as dalcetrapib and anacetrapib, that do not share the off-target effects of torcetrapib. 9 -11 The present analysis showing that treatment with torcetrapib improved glycemic control in the 6661 patients with diabetes mellitus in the ILLUMINATE trial raises the exciting possibility that inhibition of CETP may not only be antiatherogenic but may also be antidiabetic.
Methods

Study Design
ILLUMINATE was a prospective, randomized, multicenter, doubleblind clinical trial, details of which have been published previously. 7 In brief, men and women aged 45 to 75 years were eligible if they had a prior history of myocardial infarction, stroke, acute coronary syndrome, unstable angina, peripheral vascular disease, or cardiac revascularization within the period of 30 days to 5 years before screening. Patients with type 2 diabetes mellitus without prior cardiovascular disease who met American Diabetes Association criteria or who were currently on hypoglycemic agents were also eligible. A total of 15 067 patients were enrolled in the trial, of whom 6661 had diabetes mellitus. Of these, 2772 had a history of diabetes mellitus without evidence of cardiovascular disease.
During a 4-to 10-week run-in phase, subjects were given lifestyle counseling and administered atorvastatin, which was titrated at 2-week intervals, if needed, to achieve a low-density lipoprotein cholesterol level of Ͻ2.6 mmol/L. Subjects achieving the lowdensity lipoprotein cholesterol goal were randomized to receive either a combination of atorvastatin (at the dosage established during the run-in period) plus torcetrapib 60 mg or atorvastatin alone plus corresponding placebo tablets. Once randomized, subjects had scheduled study visits at 1, 3, 6, and 12 months after randomization. Thereafter, they were to be seen on a semiannual basis until study completion. The study was independently monitored for patient safety and data quality by a data safety monitoring board supported by an independent statistical data analysis center.
Glucose, insulin, hemoglobin A 1c (HbA 1c ), and HDL cholesterol were all measured at a central laboratory (MDS, Inc, Toronto, Ontario, Canada) with the use of standard techniques. HDL cholesterol was determined enzymatically with the use of polyethylene glycol-modified cholesterol esterase, cholesterol oxidase, and dextran sulfate to generate peroxide that was measured calorimetrically. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as follows: glucose (mmol/L)ϫinsulin (mU/L) divided by 22.5. 12
Statistical Methods
Summary statistics were computed and reported for each treatment group. The comparability of baseline characteristics between the 2 treatment groups was analyzed, and P values were reported on the basis of the nonparametric Wilcoxon rank sum test for continuous variables and the Fisher exact test for categorical data.
Effects of treatment with atorvastatin versus the combination of atorvastatin and torcetrapib on plasma glucose, HbA 1c , and HDL cholesterol were assessed by a linear mixed-effects model with repeated measurements analysis at baseline, 1 month, 3 months, 6 months, and 12 months. The analysis includes rank-transformed plasma data as the dependent variable, treatment as the major factor, and follow-up time (at months 1, 3, 6, and 12) as the repeated factor. In the case of insulin and HOMA-IR, for which we have follow-up data at only the 3-month time point, effects of treatment were assessed by the 1-way ANCOVA model.
Within-treatment comparisons for the change from baseline values in 3-month glucose, 3-month insulin, 6-month HbA 1c , and 3-month HOMA-IR were analyzed by the Wilcoxon signed rank test, stratified by subjects with and without diabetes mellitus. Because this analysis included only 1 follow-up time point for changes from baseline for each of the aforementioned variables, the betweentreatment comparisons with respect to these variables in subjects with or without diabetes mellitus were assessed by the 1-way ANCOVA model. The model includes rank-transformed change from baseline data as the dependent variable and treatment as the only factor adjusting for baseline value and change in 3-month (or 6-month) HDL cholesterol as the covariates.
All analyses were performed with the use of SAS Statistical Software version 8.2; the statistical significance threshold was declared at the customary (2-sided) level of 0.05.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Participants With Diabetes Mellitus
Baseline characteristics of the 6661 subjects with diabetes mellitus are presented in Table 1 . At baseline, all diabetic patients were receiving oral antidiabetic therapy. At baseline, insulin was used by 10.0% of the subjects taking atorvastatin only and 9.1% of those taking torcetrapib plus atorvastatin (Pϭ0.24). There were no reports of antidiabetic therapy being stopped in any subject during follow-up in either group. Rather, during follow-up, 200 patients (5.90%) in the atorvastatin only group and 165 (5.04%) in the torcetrapib plus atorvastatin group (Pϭ0.13) had insulin added to their therapy, and additional oral antidiabetic therapy was prescribed in 456 (13.45%) of the diabetics in the atorvastatin only group and 394 (12.05%) of those in the torcetrapib plus atorvastatin group (Pϭ0.09). The specific oral agent that was added was not recorded in most cases.
Plasma Glucose
At baseline, the fasting plasma glucose level was similar in the 2 groups ( Table 2 ). After 1 month of treatment, the level of glucose increased from 7.68 to 7.83 mmol/L (PϽ0.0001) in the atorvastatin alone group, whereas in subjects taking atorvastatin plus torcetrapib, the level of glucose decreased from 7.69 to 7.58 mmol/L (Pϭ0.0041) such that there was now a difference of 0.25 mmol/L between the 2 groups (PϽ0.0001). After 3 months of treatment, the glucose level in the group treated with the combination of atorvastatin and torcetrapib was 0.34 mmol/L lower than in the group receiving atorvastatin alone (PϽ0.0001). This difference between the 2 groups remained apparent after 6 months (0.22 mmol/L; PϽ0.0001) and 12 months (0.26 mmol/L; PϽ0.0001) of treatment ( Table 2) .
Hypoglycemia (defined in this study as a glucose level Ͻ50 mg/dL) was encountered infrequently in either the diabetic or nondiabetic subjects. In the nondiabetic subjects, a value of Ͻ50 mg/dL was recorded in the atorvastatin only and the torcetrapib/atorvastatin arms, respectively, in 1 versus 2 (Pϭ1.0000; NS) at the 1-month visit, 0 versus 0 (PϭNS) at the 3-month visit, 3 versus 2 (Pϭ0.6826; NS) at 6 months, and 2 versus 0 (Pϭ0.2421; NS) at 12 months. In the diabetic subjects, a value of Ͻ50 mg/dL was recorded in the atorvastatin only and the torcetrapib/atorvastatin arms, respectively, in 3 versus 1 (Pϭ0.6251; NS) at the 1-month visit, 1 versus 5 (Pϭ0.1185; NS) at 3 months, 5 versus 6 (Pϭ0.7706; NS) at 6 months, and 3 versus 8 (Pϭ0.1391; NS) at 12 months. In the total cohort, hypoglycemia was reported as a serious adverse event in 3 subjects taking atorvastatin only and 11 of those taking torcetrapib plus atorvastatin. The corresponding numbers reported as (not serious) adverse events were 71 and 63.
Serum Insulin
Torcetrapib also had a significant effect on the level of fasting serum insulin. At baseline, insulin levels were similar in the 2 groups (Table 2 ). Three months of treatment with atorvastatin alone was associated with a small but significant increase (Pϭ0.02) in fasting serum insulin, whereas treatment with atorvastatin plus torcetrapib resulted in a highly significant decrease (PϽ0.0001) in the serum insulin level. After 3 months of treatment, fasting serum insulin in subjects treated with atorvastatin plus torcetrapib was 11.7 U/mL lower than in those receiving atorvastatin alone (PϽ0.0001) ( Table 2) .
Hemoglobin A 1c
There were also effects of torcetrapib on the level of HbA 1c . At baseline, HbA 1c levels were similar in the 2 groups. After 1 month, the HbA 1c level was significantly lower in the torcetrapib plus atorvastatin group than in the atorvastatin only group (6.95% versus 7.07%; PϽ0.0001). The difference between the groups was even greater after 6 months of treatment when the HbA 1c level had risen to 7.29% in the subjects taking atorvastatin only, whereas it was 7.06% in those taking both atorvastatin and torcetrapib (PϽ0.0001). The difference in levels of HbA 1c in the 2 groups persisted to 12 months of treatment ( Table 2) .
High-Density Lipoprotein Cholesterol
Consistent with the observations in the total ILLUMINATE cohort, the concentration of HDL cholesterol in the diabetic subjects was increased substantially in the group receiving torcetrapib. At baseline, mean level of HDL cholesterol was 1.23 mmol/L in both the atorvastatin only and atorvastatin plus torcetrapib groups ( Table 2 ). There was minimal change in the level of HDL cholesterol over 12 months of treatment with atorvastatin alone, whereas HDL cholesterol rose progressively to 2.05 mmol/L (PϽ0.001) after 12 months of treatment with atorvastatin plus torcetrapib, representing a 66.8% increase ( Table 2) .
Homeostasis Model Assessment of Insulin Resistance
The observation that treatment with the combination of torcetrapib and atorvastatin compared with atorvastatin alone was associated with significantly lower levels of plasma glucose and HbA 1c and also with lower fasting serum insulin levels suggested that the treatment may have improved insulin sensitivity.
Indeed, after 3 months of treatment, insulin resistance (as quantified by HOMA-IR) decreased from 49.1 to 47.3 (PϽ0.0001) in subjects receiving the combination of torcetrapib and atorvastatin compared with a nonsignificant increase (Pϭ0.18) in those treated with atorvastatin alone ( Table 2) .
Relationship Between Changes in High-Density Lipoprotein Cholesterol and the Torcetrapib-Induced Effects on Glucose, Insulin, HbA 1c , and Homeostasis Model Assessment of Insulin Resistance
Analyses were conducted to determine whether the effects of torcetrapib on glucose, insulin, HbA 1c , and HOMA-IR were related to changes in the concentration of HDL cholesterol.
The magnitude of the increase in HDL cholesterol in the patients treated with torcetrapib did not predict the changes in glucose, insulin, or HbA 1c , with correlations between the change in HDL cholesterol and changes in glucose, insulin, and HbA 1c failing to achieve statistical significance. However, when the differences in glucose, insulin, and HbA 1c between the 2 groups were adjusted for the change in HDL cholesterol, the statistical significance of these differences was attenuated (Table 3 ). In the case of insulin, the highly significant difference between the 2 groups at the 3-month time point was no longer significant after adjustment for the 3-month change in HDL cholesterol. Because only a small proportion of the subjects had HbA 1c measured at the 3-month time point, the impact of change in HDL cholesterol HOMA-IR indicates homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein. *P values were based on repeated-measures ANOVA model including rank-transformed plasma data as the dependent variable, treatment as the major factor, and follow-up time (at months 1, 3, 6, and 12) as the repeated factor.
Table 3. Between-Treatment Comparison of Changes in Glucose, Insulin, Hemoglobin A 1c , and HOMA-IR Adjusted for Change in HDL Cholesterol
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on the difference in HbA 1c between the 2 groups was assessed at the 6-month (rather than 3-month) time point. The observed highly significant difference between the 2 groups was again attenuated after adjustment for the 6-month change in HDL cholesterol. In the case of HOMA-IR, the observed highly significant difference between the 2 groups after 3 months of treatment was also attenuated after adjustment for the change in HDL cholesterol (Table 3) . When the differences in glucose, insulin, and HbA 1c between the 2 groups were adjusted for changes in apolipoprotein A-I, changes in the major HDL protein, and changes in HDL cholesterol plus changes in apolipoprotein A-I, the significance of the differences between the 2 groups was attenuated to an extent similar to that observed after adjustment for changes in HDL cholesterol alone (data not shown).
Participants Without Diabetes Mellitus
Torcetrapib also lowered both glucose and insulin levels in the participants without diabetes mellitus, although the effects were not as great as in those with diabetes mellitus. At baseline, there was no significant difference between the levels of plasma glucose, serum insulin, or HOMA-IR in the 2 groups. However, after 3 months of treatment, both glucose and insulin levels were lower, as was HOMA-IR in the group receiving the combination of torcetrapib plus atorvastatin compared with the group receiving atorvastatin alone (PϽ0.0001 for all) ( Table 4 ). The fact that only a small proportion of the nondiabetic subjects had HbA 1c measured at any time point (Table 4 ) limits conclusions regarding effects of treatment on HbA 1c in the participants without diabetes mellitus. In contrast to the observation in subjects with diabetes mellitus, when the differences in glucose, insulin, and HOMA-IR between the treated and control groups of nondiabetic patients were adjusted for the change in HDL cholesterol, the statistical significance of the differences was unchanged ( Table 3 ). The number of reported cases of new-onset diabetes mellitus was small in both treatment arms in this 12-month analysis. Among the evaluable subjects who did not have diabetes mellitus at baseline, new-onset diabetes mellitus was reported in 95 of 3983 subjects (2.39%) in the atorvastatin only arm and in 76 of 4126 subjects (1.84%) in the torcetrapib/atorvastatin arm (Pϭ0.09).
Discussion
Diabetic patients in the ILLUMINATE trial who received the combination of atorvastatin plus torcetrapib had lower levels of both plasma glucose and HbA 1c than those receiving atorvastatin alone, indicating that treatment with torcetrapib, compared with placebo, resulted in an improvement in diabetic control. The fact that the level of fasting serum insulin was also lower in those taking torcetrapib suggested that the drug may have reduced insulin resistance, a conclusion supported by the observation of lower values of HOMA-IR in the diabetic patients treated with torcetrapib. This result was not expected because it is known that torcetrapib increased the plasma level of aldosterone, 7 an effect that would be predicted to worsen rather than improve diabetic control. 13 Furthermore, the improvement in diabetic control in patients taking torcetrapib plus atorvastatin compared with those taking atorvastatin alone occurred despite the fact that more patients in the atorvastatin only group were given add-on insulin and oral antidiabetic therapy during followup. This suggests that the true beneficial effect of torcetrapib on glucose homeostasis may have been even greater than indicated by the observed differences in glucose, insulin, and HbA 1c between the 2 groups. This result is consistent with the earlier observation of a lower level of plasma glucose in patients with a genetic deficiency of CETP. 6 An obvious question arises: Were these beneficial effects of torcetrapib on glucose homeostasis the consequence of changes in plasma lipid levels secondary to CETP inhibition, or did they reflect an off-target effect of the drug unrelated to inhibition of CETP?
Some well-documented adverse effects of torcetrapib are unrelated to CETP inhibition. 8, 10, 11 These include induction of the synthesis and release of aldosterone and cortisol from adrenal cortical cells 11 and an associated increase of blood pressure, increase in serum sodium and bicarbonate, and decrease in serum potassium. 7 There is mounting circumstantial evidence that these off-target effects accounted for the harm caused by torcetrapib in the ILLUMINATE trial. It is therefore possible that the effects of torcetrapib on glucose homeostasis observed in the present analysis represented an additional off-target effect of the drug that, in this case, was beneficial rather than adverse, although the true mechanism of this effect cannot be determined from this post hoc analysis Within-treatment comparison PϽ0.0001 PϽ0.0001
HOMA-IR indicates homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein; and IQR, interquartile range. P values for between-treatment comparisons were assessed by Wilcoxon rank sum test. P values for within-treatment comparison of change from baseline value were based on Wilcoxon signed rank test and for between-treatment comparisons of change from baseline data were based on 1-way ANCOVA model including rank-transformed change from baseline data as the dependent variable and treatment as the only factor adjusting for baseline value and change in 3-month (or 6-month) HDL cholesterol as the covariates.
of a randomized clinical trial. There was a suspicion that the improvement in diabetic control in subjects treated with torcetrapib may have been related (at least in part) to the increase in concentration of HDL cholesterol, although the fact that the torcetrapib-induced changes in levels of glucose, HbA 1c , and insulin did not correlate significantly with the magnitude of the increase in HDL cholesterol does not support such a suggestion and points to the fact that other mechanisms may have been operating. However, the possibility that an increase in HDL concentration may have contributed to the improvement in diabetic control is consistent with reported experimental evidence that HDLs have potential antidiabetic properties. 4, 14 Some lipid-modifying agents, including statins and niacin, have an adverse effect on glucose homeostasis, including a possible increase in new-onset diabetes mellitus. 15, 16 The mechanism of this effect is not known. There is evidence that an increase in the cholesterol content of pancreatic ␤-islet cells decreases insulin secretion. 17 However, given that statin treatment will, if anything, decrease cellular cholesterol levels, this is an unlikely explanation for the observed increase in new-onset diabetes mellitus. It is possible that statins decrease insulin sensitivity in the liver or muscle, although there is no direct experimental evidence to support this. Thus, it is currently not known why statins adversely affect glucose homeostasis, nor is it understood how niacin exerts an adverse effect on diabetic control. In the present study, there was clear evidence of an adverse effect of atorvastatin on diabetic control ( Table 2 ). The addition of torcetrapib prevented an atorvastatin-induced worsening of diabetic control with evidence that it actually improved glycemic control compared with baseline values. It is possible that the true effect of torcetrapib may have been even greater than observed when one considers that add-on antidiabetic therapy during follow-up was prescribed more frequently in the patients taking atorvastatin alone.
It should be emphasized that the present analysis provides little understanding of the mechanism by which torcetrapib improved diabetic control. It should also be emphasized that the analysis was post hoc and data driven. However, this in no way diminishes the potential importance of the observation, especially when one considers that trials designed to test the atheroprotective properties of the CETP inhibitors dalcetrapib 18 and anacetrapib, 19 which do not share the adverse off-target effects of torcetrapib, are ongoing. Given that results with torcetrapib may not be generalizable to other CETP inhibitors, 20 it will be of great interest to see whether dalcetrapib and anacetrapib also improve diabetic control. HOMA-IR indicates homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein. *P values were based on repeated-measures ANOVA model including rank-transformed plasma data as the dependent variable, treatment as the major factor, and follow-up time (at months 1, 3, 6, and 12) as the repeated factor. corresponding author with critical input from all authors, 1 of whom (Dr Breazna) is an employee of Pfizer. The authors had final responsibility for the decision to submit the manuscript for publication.
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